Jerini AG to Wind Down its Preclinical Programs

29-Jun-2009 - Jerini AG has decided to end all negotiations regarding the transfer of assets associated with Jerini AG's preclinical programs and to terminate the employees associated with these programs. The decision was taken following unsuccessful efforts to find an investor for the sale of the preclinical ...

Jerini AG Reaches Agreement to Sell JPT Peptide Technologies GmbH to TheraCode GmbH

07-May-2009 - Jerini AG has reached an agreement to sell its wholly-owned subsidiary, JPT Peptide Technologies GmbH to TheraCode GmbH, Mainz, a wholly-owned subsidiary of BioNTech AG, Mainz. Under the terms of the agreement, TheraCode GmbH will pay Jerini AG a purchase price of approximately € 5 million in ...

Strategic Review of Jerini Assets Completed

13-Oct-2008 - Jerini AG and Shire Deutschland Investments GmbH have completed the strategic review of the assets and programs of Jerini AG, not related to Icatibant (Firazyr®), as referred to in the Offer Document published by Shire Deutschland Investments GmbH on August 13, 2008. The Jerini Supervisory Board ...

Jerini sells onself to british Shire

Jerini AG for an equity purchase price of EUR 328 million

07-Jul-2008 - Shire Limited, the global specialty biopharmaceutical company, announced that Maia Elfte Vermögensverwaltungs-GmbH, to be renamed "Shire Deutschland Investments GmbH", a German indirect subsidiary of Shire Limited, will launch a voluntary public takeover offer for shares in Jerini AG, the ...

Jerini Ophthalmic Treats First Patient in Phase I Trial for Age-related Macular Degeneration

10-Oct-2007 - Jerini AG announced that its wholly-owned subsidiary, Jerini Ophthalmic, Inc., has treated the first patient in its Phase I clinical trial evaluating JSM 6427 for the treatment of age-related macular degeneration (AMD). JSM 6427 is a small molecule in development to prevent the progression of dry ...

Jerini expands collaboration with Baxter to develop non-intraveneous hemophilia therapy

07-Feb-2007 - Jerini AG announced the expansion of their current research collaboration with Baxter AG for the development of a non-intravenous therapy for the treatment of hemophilia. The companies have initiated two additional programs aimed at novel targets, potentially offering new therapeutic developments ...

Jerini Announces Positive Results from Two Phase III Trials of Icatibant for the Treatment of Hereditary Angioedema

25-Sep-2006 - Jerini AG announced the results of its two pivotal Phase III trials (FAST-1 and FAST-2) for the subcutaneous treatment of hereditary angioedema (HAE). In the FAST-2 study, the primary endpoint was reached, showing a significant reduction in the time to onset of symptom relief. While FAST-1 ...

Jerini AG presents clinical development update for Icatibant in the treatment of hereditary angioedema

07-Mar-2006 - Jerini AG announced that clinical trial progress from its ongoing Phase III clinical trial for hereditary angioedema (HAE) was presented by Dr. Alvin Davis, Harvard Medical School, at the American Academy of Allergy Asthma and Immunology Conference Dr. Davis reported that 153 subcutaneous ...

JERINI INITIATES PIVOTAL REGISTRATION STUDY FOR ICATIBANT IN HEREDITARY ANGIOEDEMA

08-Sep-2004 - Jerini announced today the start of its US and Canadian pivotal registration study with Icatibant for the treatment of hereditary angioedema (HAE). An Investigational New Drug Application (IND) and Clinical Trials Application (CTA) have been filed with the FDA and Health Canada, respectively. ...

PamGene and JPT Join Forces

Partnership pioneers a new approach to kinase research

24-Jun-2004 - Den Bosch/The Netherlands, Berlin/Germany: PamGene International BV and Jerini Peptide Technologies (JPT), a Division of Jerini AG, have established a collaboration to provide a new technology for kinase studies. PamGene's ability to generate kinetic read-out of multiple kinase activities on ...